Evaluation of a global screening assay for the investigation of the protein C anticoagulant pathway.
We have evaluated a global screening test for the protein C pathway, the 'ProC Global' (Dade Behring Ltd, Milton Keynes, UK). Patient groups tested included inherited protein C or S deficient and inherited/acquired activated protein C resistance. Results showed that protein C deficiencies and activated protein C resistance could be successfully detected with this test whereas deficiencies of protein S were less readily distinguished from the normal population. The ProC Global was unreliable in patients with antiphospholipid antibodies, raised plasma factor VIII:C and in those receiving oral anticoagulant therapy.
Rimmer
J E
JE
Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK.
Cooper
P C
PC
Brookfield
C J
CJ
Preston
F E
FE
Makris
M
M
D020016:Activated Protein C Resistance / Q000097:blood / Q000175:diagnosis; D001780:Blood Coagulation Tests / Q000379:methods* / Q000592:standards; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D008297:Male; D010314:Partial Thromboplastin Time; D011486:Protein C / Q000032:analysis* / Q000592:standards; D020151:Protein C Deficiency / Q000097:blood / Q000175:diagnosis; D012016:Reference Values; D012737:Sex Factors
D016682:Lupus Coagulation Inhibitor; D011486:Protein C